ArticleOncology letters2021
Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma.
Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.Frontiers in immunology · 2023Trial
- Durable complete response following sequential atezolizumab-bevacizumab and delayed transcatheter arterial embolization in advanced hepatocellular carcinoma.Clinical journal of gastroenterology · 2026Article
- Local and systemic cytokine signatures for outcome prediction after transarterial chemoembolization in hepatocellular carcinoma.Theranostics · 2026Article
- Mapping the research landscape of nanotechnology based immunotherapy for hepatocellular carcinoma.Discover oncology · 2025Article
- Immunologic effects of locoregional therapies for unresectable hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2025Article
- Role of the TLR signaling pathway in the pathogenesis of glioblastoma multiforme with an emphasis on immunotherapy.Biochemistry and biophysics reports · 2025Review
- Article
- Transarterial chemoembolization combined with lenvatinib and sintilimabWorld journal of gastrointestinal oncology · 2025Article
- First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors.Frontiers in pharmacology · 2025Article
- The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications.British journal of cancer · 2024Review
- Immune effect and prognosis of transcatheter arterial chemoembolization and tyrosine kinase inhibitors therapy in patients with hepatocellular carcinoma.World journal of gastrointestinal oncology · 2024Article
- Immune Effects of Intra-Arterial Liver-Directed Therapies.Journal of vascular and interventional radiology : JVIR · 2024Review
- Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate-stage Hepatocellular Carcinoma: A Multicenter Retrospective Study.Journal of hepatocellular carcinoma · 2024Article
- Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation.BMC cancer · 2023Article
- A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma.Journal of liver cancer · 2023Article
- Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape.International journal of molecular sciences · 2023Review
- Review
- CK5/6-positive, P63-positive lymphoepithelioma-like hepatocellular carcinoma: A case report and literature review.World journal of clinical cases · 2023Article
- Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre real-world analysis with propensity score matching.Frontiers in immunology · 2023Article
- A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study.BMC cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to investigate the effects of transarterial chemoembolization (TACE) on the immune function of patients with hepatocellular carcinoma (HCC). A total of 114 patients with HCC were selected and their peripheral blood was collected before and 1 month after TACE treatment. Flow cytometry and reverse transcription-quantitative PCR were performed to analyze the changes in immune function in patients before and after treatment. Kaplan-Meier curves were plotted for survival analysis. The programmed cell death ligand 1 (PD-L1) and programmed cell death protein 1 (PD1) expression before TACE treatment were significantly higher in patients with poor TACE response compared with those patients with well response. Higher PD-L1 mRNA expression in the peripheral blood mononuclear cells after TACE predicted a superior prognosis. After TACE treatment, the proportion of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.